Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 6/20 | 0.60 |
| ▸ | F2 | P00734 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | LIG1 | P18858 | 1/20 | 0.48 |
| ▸ | IKBKB | O14920 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6181512 | 0.89 | F2 (0.71) | DAOF2IKBKBKDM4EALDH1A1 | |
| SCHEMBL70493 | 0.87 | DAO (0.67) | DAOPKMLIG1KDM4EALDH1A1 | |
| SCHEMBL28353716 | 0.84 | DAO (0.64) | DAOPKMLIG1KDM4EALDH1A1 | |
| SCHEMBL19987844 | 0.84 | DAO (0.64) | DAOPKMLIG1KDM4EALDH1A1 | |
| SCHEMBL28343181 | 0.84 | DAO (0.64) | DAOPKMLIG1KDM4EALDH1A1 | |
| SCHEMBL11598753 | 0.84 | DAO (0.64) | DAOPKMLIG1KDM4EALDH1A1 | |
| SCHEMBL29808747 | 0.84 | DAO (0.64) | DAOPKMLIG1KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL3074364 | 0.84 | DAO (0.64) | DAOPKMLIG1KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL1979156 | 0.84 | DAO (0.64) | DAOPKMLIG1KDM4EALDH1A1 | |
| SCHEMBL27562112 | 0.84 | DAO (0.64) | DAOPKMLIG1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114206335-B | KCNT1 inhibitors and methods of use | 普拉克西斯精密药物股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| EP-4446314-A2 | KCNT1 INHIBITORS AND METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-3962479-B1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2024-07-24 | — | — | EP | disclosed |
| US-20220280476-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-09-08 | — | — | US | disclosed |
| US-20220280476-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-09-08 | — | — | US | disclosed |
| CN-114206335-A | KCNT1 inhibitors and methods of use | 普拉克西斯精密药物股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| EP-3962479-A1 | KCNT1 INHIBITORS AND METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| CN-113563320-A | Compound containing thiophene structure and application thereof in medicine | 天津药物研究院有限公司 | 2021-10-29 | — | — | CN | disclosed |
| WO-2020227097-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| WO-2020227097-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| EP-2439204-A1 | HETEROCYCLIC COMPOUND AND HEMATOPOIETIC STEM CELL AMPLIFIER | Nissan Chemical Industries, Ltd. (JP) | 2012-04-11 | — | — | EP | disclosed |
| CN-102325550-A | Combination of photodynamic therapy and anti-VEGF agents in the treatment of unwanted choroidal neovasculature | QUADRA LOGIC TECH INC | 2012-01-18 | — | — | CN | disclosed |
| US-8012956-B2 | Tropane compounds | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| CN-101910168-A | Tropane compounds | EXELIXIS INC | 2010-12-08 | — | — | CN | disclosed |
| CN-101888840-A | method of treating polycystic kidney disease using brain amide derivatives | GENZYME CORP | 2010-11-17 | — | — | CN | disclosed |
| EP-2074120-B1 | TROPANE COMPOUNDS | EXELIXIS INC (US) | 2010-03-03 | — | — | EP | disclosed |
| EP-2074120-A1 | TROPANE COMPOUNDS | Exelixis, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20090163471-A1 | Tropane compounds | EXELIXIS, INC. | 2009-06-25 | — | — | US | disclosed |
| WO-2009055077-A1 | TROPANE COMPOUNDS | EXELIXIS, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| WO-2006064286-A1 | CATHEPSIN S INHIBITORS | MEDIVIR UK LTD (GB) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220280476-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | DAO 1619/4885F2 4840/4885PKM 725/4885 |
| US-20090163471-A1 | Tropane compounds | ADRA1B, ADRA2B, ADRB2 | DAO 4435/4885F2 233/4885PKM 3578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.